Lucie Ann Fremeau-Fernandez’s Post

Immunic Therapeutics (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month, highlighting the disease's impact, development, and the unmet medical needs of patients. MS, a lifelong autoimmune disease more prevalent in women than men, begins typically in early adulthood. It manifests in various forms, starting with relapsing-remitting MS, characterized by relapses and MRI lesions, affecting 80-85% of patients. #NASDAQ #IMUX Watch at #Proactive #ProactiveInvestors http://ow.ly/wjMZ105mny4

  Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is making significant strides in regenerative medicine with its ADAPT clinical trial for lower back pain caused by Degenerative Disc Disease. Intervertebral disc degeneration, often due to a lack of blood flow, is a leading contributor to lower back pain, affecting a vast number of individuals worldwide. Current treatments primarily address symptoms rather than the underlying cause, leaving room for innovative approaches like CELZ-201-DDT to potentially revolutionize the field and improve patient outcomes. Don't miss the opportunity to stay informed about this groundbreaking research!    https://lnkd.in/df9jcNii   #ClinicalTrials #BackPain #RegenerativeMedicine #Innovation

  Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is making significant strides in regenerative medicine with its ADAPT clinical trial for lower back pain caused by Degenerative Disc Disease. Intervertebral disc degeneration, often due to a lack of blood flow, is a leading contributor to lower back pain, affecting a vast number of individuals worldwide. Current treatments primarily address symptoms rather than the underlying cause, leaving room for innovative approaches like CELZ-201-DDT to potentially revolutionize the field and improve patient outcomes. Don't miss the opportunity to stay informed about this groundbreaking research!    https://lnkd.in/dH7AjYdt   #ClinicalTrials #BackPain #RegenerativeMedicine #Innovation

EXCITING ANNOUNCEMENT!! LightMD, Inc. and Applied BioPhotonics are pleased to announce the recent publication of our long-awaited invited paper: “The Emerging Role of Photobiomodulation in COVID-19 Therapy” by the European Society of Medicine. The paper, available by direct download from the journal ESMED, is split into two parts, each downloadable separately by clicking on the following links: Part I Deep-Tissue PBM Modality and Regimen for Treating SARS-CoV-2 Infections https://lnkd.in/eVuj8AKY Part II Whole Organ PBM Case Studies for Acute & Long COVID https://lnkd.in/ewN5zju6 Colleagues who have reviewed the papers tell us the publication represents the most comprehensive work on the treatment of infectious inflammatory disease using photobiomodulation ever written. In aggregate with 86 pages of text, 25 figures, and 531 references analyzing over a dozen PBM case studies involving the treatment of hundreds of acute and long COVID-19 patients We hope you will agree with the reviews. Richard K Williams CEO, CTO Applied BioPhotonics Ltd. CEO, CSO LightMD Inc. Dan Schell  President LightMD Inc Cofounder Applied BioPhotonics Ltd.

Looking forward to sharing our posters at #isporeurope on Monday 13th November 2023 EE92: Introduction to the Duchenne Muscular Dystrophy Burden-of-Illness Study Expanded (US and Spain) RWD63: Clinical Outcomes in Non-Inhibitor Severe Haemophilia A Patients Receiving Prophylaxis Across Currently Available Haemophilia A Treatments: Insights Form the 'Cost of Haemophilia: A Socioeconomic Survey III' (CHESS III Study) PCR65: Assessment of the EQ-5D and DMD QoL for Duchenne Muscular Dystrophy: A patient and Caregiver Study

Given todays exciting 2-year results from Iveric Bio, An Astellas Company’s GATHER2 study, this post just seems timely! We at the Eye Clinic of Wisconsin are glad to be the first clinic in the state to offer Izervay, a unique treatment for geographic atrophy (GA) secondary to Age Related Macular Degeneration (AMD), to our wonderful patients. GA is truly a public health crisis—it is a disease that causes irreversible vision loss, is under diagnosed and has limited treatment options to date. With Izervay, retina specialists now have an expanding toolkit to combat this relentless disease. Being one of the first in the country to use this drug means that my patients can get a head start in the battle against vision loss! #izervay #complimentinhibitor #retina #ophthalmology #dryamd #geographicatrophy #maculardegeneration #wetamd #gather2 #c5 #antivegf #intravitrealinjection #ivericbio #eyeclinicofwisconsin #optometry

Yesterday, our New York office wore purple in support of Alzheimer's Awareness Month. At GQR, we stand united in our commitment to raise awareness and contribute to the fight against Alzheimer's and other brain disorders. June marks a crucial period to spotlight the millions affected by these conditions. Our dedication to advancing the pharmaceutical field is at the heart of our mission to drive meaningful change and improve lives. 🔬 Innovation and Expertise: As a leading partner in the pharmaceutical industry, GQR Life Sciences is at the forefront of groundbreaking research and development. We tirelessly support the discovery of new treatments and therapies that hold the promise of a brighter future for those living with Alzheimer's and other neurological conditions. 💜 Community and Care: Real progress comes from collaborative effort. By working closely with our clients, researchers, and healthcare professionals, we foster an environment where innovation thrives and compassionate care is prioritized. 🌍 Global Impact: With our global reach, we connect top talent with cutting-edge projects worldwide. We are proud to contribute to a collective mission that spans continents, bringing us closer to breakthroughs that can transform lives. Join us this month in spreading awareness and supporting those affected by Alzheimer's. Together, we can drive the change needed to combat this devastating disease. #GQRlifesciences #GQRcares #LifeatGQR #alzheimersawareness #GQR

🔊𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸 𝗙𝗗𝗔 𝗦𝘁𝘂𝗱𝘆 𝗗𝗲𝗺𝗼𝗻𝘀𝘁𝗿𝗮𝘁𝗲𝘀 𝗦𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗼𝗳 𝗟𝘂𝗺𝗯𝗮𝗿 𝗙𝗮𝗰𝗲𝘁 𝗔𝗿𝘁𝗵𝗿𝗼𝗽𝗹𝗮𝘀𝘁𝘆 𝗢𝘃𝗲𝗿 𝗙𝘂𝘀𝗶𝗼𝗻 𝗳𝗼𝗿 𝗦𝗽𝗶𝗻𝗮𝗹 𝗦𝘁𝗲𝗻𝗼𝘀𝗶𝘀 𝗮𝗻𝗱 𝗦𝗽𝗼𝗻𝗱𝘆𝗹𝗼𝗹𝗶𝘀𝘁𝗵𝗲𝘀𝗶𝘀! Our latest published study proves that lumbar facet arthroplasty significantly outperforms traditional spinal fusion in treating patients with Grade I degenerative spondylolisthesis and stenosis, showcasing superior clinical success and improved patient outcomes. #PremiaSpine #SuperiorOutcomes #TOPS #FacetArthroplasty

📣 Great success - with almost 500 participants - for the #EUSOMA led webinar yesterday evening, aimed at presenting and discussing real clinical cases with a variety of pathological entities and different risk of malignancy, focusing on the importance of adequate classification and multidisciplinary discussion which is essential to ensure radiological and pathological concordance for the diagnosis of B3 lesions. 🔗 The webinar follows the recent publication of "European Guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions)" ➡️ https://lnkd.in/dXP49_ny 🙏 Marzia Zambon, co-author of the Guidelines for the section regarding communication and risk factor management, spoke about the specific challenges of doctor – patient communication when dealing with the uncertainties of a B3 lesion diagnosis.   #EUSOMA #EUSOBI ESP (BWG) #ESSO

📽️ During the recent ALL Hub Steering Committee Meeting, Charles Mullighan chaired a discussion on strategies to optimize outcomes in pediatric/AYA patients receiving CAR T cells. KEY DISCUSSION POINTS: ▪️ Key factors for CAR T-cell success or failure ▪ How to manage relapse after CAR T-cell therapy ▪ Issues that should be considered when optimizing CAR T-cell therapy outcomes in pediatric/AYA patients Click here to watch the informative discussion 👉 https://loom.ly/NrT_T5c #allsm #leusm